



CHARITY COMMISSION
FOR ENGLAND AND WALES

Trustees' Annual Report for the period

From 10/10/2023 to 05/04/2025

Charity name: The Immuno Oncology Clinical Network (IOCN)

Charity registration number: 1205140

Objectives and Activities

The main purposes of the Immuno-Oncology Clinical Network are to promote and protect the health of the public, and particularly those undergoing immuno-oncology therapies, by:

- Providing education and advice to health care professionals involved in the delivery of such therapies.
- Promote and support research (provided that the useful results of such research will be published or disseminated) or other similar activities which will advance knowledge and understanding of immuno-oncology treatments and the associated side effects

The charity's main activities are the provision of education and training, clinical support, providing guidance on immuno-oncology policy and governance, and support for healthcare professionals developing immuno-oncology services.

The trustees confirm that they have had due regard to the guidance issued by the Charity Commission on public benefit. In particular, the trustees have considered how the charity's activities further its charitable purposes for the public benefit. The trustees believe that the charity has complied with the duty in section 17 of the Charities Act 2011 to have regard to the Charity Commission's guidance on public benefit when exercising their powers and duties.

The IOCN recognises the contribution of 25 volunteers who supported the delivery of its educational programme, including online webinars and one in-person event. In addition, 20 volunteers contributed to the charity's education and policy and governance pillar.

The IOCN does not make grants to individuals or organisations and does not provide funding to other charities.

Achievements and Performance

During the reporting period the IOCNs main charitable achievements included:

- The charity delivered free monthly educational webinars for healthcare professionals on immuno-oncology treatments and the management of associated side effects, including the *Ask a Question* and *New and Novel* webinar series.

- The charity provided in-person education on immuno-oncology treatments, including the *Case Conundrums* event held in March 2025 and a number of collaborative events delivered in partnership with SBK Healthcare Events.
- The charity supported the development of consensus statements to promote good practice, including the *Baseline Cardiac Biomarkers Statement* produced in collaboration with the British Cardio-Oncology Society (BCOS).
- The charity developed patient information including a leaflet on checkpoint inhibitors to support patients' understanding of treatment logistics, practical considerations, and potential immune-mediated side effects.
- In collaboration with the British Oncology Pharmacy Association (BOPA), the charity contributed to the publication of immunosuppressant monographs providing guidance on their prescribing and monitoring for the management of immune-related adverse events associated with immune checkpoint inhibitor therapy.
- The Charity developed the IOCN website as a single, accessible resource for healthcare professionals, providing clinical guidelines, patient information and resources, and network contact details.

These activities directly support the charity's objectives by improving clinical knowledge, promoting safe delivery of immuno-oncology treatments, and supporting healthcare professionals, thereby benefiting patients receiving such therapies.

Future plans:

In the next reporting period, the charity plans to expand its educational programme, continue the development of clinical guidance, produce additional patient information resources, address key policy and governance issues affecting healthcare professionals managing patients receiving immuno-oncology treatments, and further support healthcare professionals in the development of immuno-oncology services.

Financial Review

Income and Expenditure

- **Total incoming resources:** £55,928
- **Total resources expended:** £21,100

The trustees consider that maintaining reserves equivalent to 4-6 months of core operating costs is appropriate to ensure financial stability and continuity of services in the event of funding delays or unexpected expenditure. This equates for a minimum of £5000. The charity held no restricted funds at the reporting date and there were no funds in material deficit.

The trustees have considered the charity's financial position and future funding. They have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future, and accordingly the accounts have been prepared on a going concern basis. The trustees are not aware of any material uncertainties that may cast significant doubt on the charity's ability to continue as a going concern.

Funding sources:

The IOCN's funding sources include sponsorship (both restricted and unrestricted), grants, and donations from pharmaceutical and biotechnology companies committed to improving outcomes for cancer patients receiving immuno-oncology treatments. The trustees have appropriate policies in place to manage conflicts of interest and to ensure the charity's independence in its educational and clinical activities.

In addition, the IOCN generates income from registration fees paid by delegates attending its in-person educational events.

Risk assessment:

The trustees have identified and reviewed the principal risks facing the charity and have implemented appropriate controls and policies to mitigate those risks. The principal risks identified are:

1. **Financial sustainability** – The charity is currently largely dependent on pharmaceutical industry funding, which could affect its ability to continue delivering activities if income were reduced or delayed. This risk is mitigated through regular financial monitoring, the maintenance of appropriate reserves, and efforts to diversify income sources, including seeking funding from biotechnology companies and exploring membership options for educational activities.
2. **Dependence on key individuals and volunteers** – The charity relies on a small number of trustees, volunteers, and senior personnel with specialist expertise. The trustees mitigate this risk through succession planning, active trustee recruitment, and clear role descriptions and procedures. The charity has planned a step-by-step approach to additional volunteer recruitment in order to increase volunteer numbers while supporting sustainable growth.

Structure, Governance and Management

The IOCN is a Charitable Incorporated Organisation (CIO) governed by a single constitution and does not hold or administer any separate trusts.

The Charity selects Trustees in accordance with its 'Appointment of New Trustees' policy. The IOCN appoints trustees to fill vacancies or strengthen the board's skills and experience, following an agreed and transparent recruitment process. The Trustees will either advertise a trustee position openly or a candidate can be nominated by the other trustees or by another organisation. Trustees are appointed following appropriate vetting, conflict-of-interest checks, and an induction process.

The charity is run by a small voluntary executive team comprising the Chief Executive Officer, Deputy Chief Executive Officer and Operations Director. The executive team oversees the day-to-day running of the charity and its paid administrators.

Reference and Administrative details

Charity name	The Immuno-Oncology Clinical Network
Other name the charity uses	The IOCN
Registered charity number	1205140
Charity's principal address	IO Clinical Network PO BOX 303, Liverpool L22 2AA

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Anna Olsson-Brown		Oct 2023 – present	
2	Alexandra Johnson		Oct 2023 – present	
3	Ricky Frazer		Oct 2023 – present	
4	Clare Barlow		Oct 2023 – present	
5	Alice Tew		Feb 2025- present	
6	Brent O’Carrigan		Oct 2023 – present	
7	Alison Hodge		Feb 2025- present	
8	Trudy Guinan		Oct 2023 – present	
9	Kate Young		Oct 2023 – present	
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Corporate trustees – names of the directors at the date the report was approved

[illegible]

Name of trustees holding title to property belonging to the charity

[illegible]

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	No funds or objects of the charity are held by trustees.
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

--

Other optional information

--

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)



Full name(s)

Dr Alexandra Diana Johnson

Position (eg Secretary,
Chair, etc)

Trustee

Date

30/1/26

**Report of the Trustees and
Unaudited Financial Statements
for the Year Ended 30 April 2025
for
Immuno-Oncology Clinical Network**

Bennett Brooks & Co Ltd
Chartered Accountants
Cherry Tree Court
Cross Street
Leek
Staffordshire
ST13 6BL

Immuno-Oncology Clinical Network

Contents of the Financial Statements
for the year ended 30 April 2025

	Page
Report of the Trustees	1
Independent Examiner's Report	2
Statement of Financial Activities	3
Balance Sheet	4
Notes to the Financial Statements	5 to 6
Detailed Statement of Financial Activities	7

Immuno-Oncology Clinical Network

Report of the Trustees
for the year ended 30 April 2025

The trustees present their report with the financial statements of the charity for the year ended 30 April 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1205140

Principal address

PO Box 303
Liverpool
L22 2AA

Trustees

Ms A C Olsson-Brown
Dr A Johnson
Miss T Guinan
Mrs A Tew
Dr K Young
Dr R Frazer
Miss A Hodge
Dr C Barlow


Independent Examiner

Bennett Brooks & Co Ltd
Chartered Accountants
Cherry Tree Court
Cross Street
Leek
Staffordshire
ST13 6BL

02-Dec-2025

Approved by order of the board of trustees on and signed on its behalf by:

Signed by:



952933468A354E4.....

Ms A C Olsson-Brown - Trustee

**Independent Examiner's Report to the Trustees of
Immuno-Oncology Clinical Network**

Independent examiner's report to the trustees of Immuno-Oncology Clinical Network

I report to the charity trustees on my examination of the accounts of Immuno-Oncology Clinical Network (the Trust) for the year ended 30 April 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed by:

A0DBC881CA07414...

Mrs C Hambleton

Bennett Brooks & Co Ltd
Chartered Accountants
Cherry Tree Court
Cross Street
Leek
Staffordshire
ST13 6BL

08-Dec-2025

Date:

Immuno-Oncology Clinical Network

Statement of Financial Activities
for the year ended 30 April 2025

	Notes	Unrestricted fund £
INCOME AND ENDOWMENTS FROM		
Donations and legacies		55,928
		<hr/>
EXPENDITURE ON		
Raising funds	2	21,036
Other		64
		<hr/>
Total		21,100
		<hr/>
NET INCOME		34,828
		<hr/>
TOTAL FUNDS CARRIED FORWARD		34,828
		<hr/> <hr/>


Immuno-Oncology Clinical Network

Balance Sheet
30 April 2025

	Notes	Unrestricted fund £
FIXED ASSETS		
Tangible assets	4	256
CURRENT ASSETS		
Cash at bank		35,052
CREDITORS		
Amounts falling due within one year	5	(480)
NET CURRENT ASSETS		34,572
TOTAL ASSETS LESS CURRENT LIABILITIES		34,828
NET ASSETS		34,828
FUNDS	6	
Unrestricted funds		34,828
TOTAL FUNDS		34,828

02-Dec-2025

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:

Signed by:

952933468A354E4.....
A C Olsson-Brown - Trustee

Immuno-Oncology Clinical Network

Notes to the Financial Statements
for the year ended 30 April 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on reducing balance

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. RAISING FUNDS

Raising donations and legacies

Support costs	£ (6,412)
---------------	--------------

3. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2025.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2025.

Immuno-Oncology Clinical Network

Notes to the Financial Statements - continued
for the year ended 30 April 2025

4. TANGIBLE FIXED ASSETS

	Fixtures and fittings £
COST	
Additions	320
DEPRECIATION	
Charge for year	64
NET BOOK VALUE	
At 30 April 2025	256

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	£
Other creditors	480

6. MOVEMENT IN FUNDS

	Net movement in funds £	At 30.4.25 £
Unrestricted funds		
General fund	34,828	34,828
TOTAL FUNDS	34,828	34,828

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	55,928	(21,100)	34,828
TOTAL FUNDS	55,928	(21,100)	34,828

7. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2025.

Immuno-Oncology Clinical Network

**Detailed Statement of Financial Activities
for the year ended 30 April 2025**

£

INCOME AND ENDOWMENTS

Donations and legacies

Grants	10,000
Subscriptions	1
Donated services and facilities	45,927
	<hr/>
	55,928
	<hr/>

Total incoming resources	55,928
---------------------------------	--------

EXPENDITURE

Other trading activities

Purchases	4,664
-----------	-------

Other

Fixtures and fittings	64
-----------------------	----

Support costs

Management

Professional services	3,673
Postage and stationery	1,183
Advertising	5,265
Sundries	3,085
Travel expenses	1,329
No description	621
	<hr/>
	15,156

Information technology

Repairs and renewals	736
----------------------	-----

Governance costs

Accountancy and legal fees	480
	<hr/>

Total resources expended	21,100
	<hr/>

Net income	<u><u>34,828</u></u>
-------------------	----------------------

